The Substance Abuse Prevention and Treatment Block Grant (SABG) program provides funding to all 50 states, the District of Columbia, Puerto Rico, and the U. S. UU. to support primary substance abuse prevention strategies.
The mission of the Substance Abuse and Mental Health Services Administration (SAMHSA) is to lead public health initiatives and service delivery that promote mental health, prevent substance abuse, and provide treatments and supports to promote recovery, while ensuring equitable access and better outcomes. The Collaborative Performance Division of the Center for Substance Abuse Treatment (CSAT) of SAMHSA, in collaboration with the Division of State Programs of the Center for Substance Abuse Prevention (CSAP), administers the SABG. The program should target both the general population and subgroups that are at high risk of substance abuse. Federal regulations apply to states, local governments, and religious organizations that receive global grants for substance abuse prevention and treatment or transition assistance projects after homelessness, or both grants.
SAMHSA also has discretionary powers to grant grants, providing the HHS Secretary with more flexibility to respond to individuals and communities in need of mental health and substance abuse services. One of the drugs in short supply is Carboplatin, a chemotherapeutic agent used as a first-line treatment for several types of cancer. The SAMHSA Center for Substance Abuse Prevention is responsible for overseeing HHS certified laboratories that operate according to the mandatory guidelines of federal workplace drug testing programs. CARA also reauthorizes a grant program for residential treatment of pregnant and postpartum women and their children against opioid addiction, and creates a pilot program for state substance abuse agencies to address gaps detected in the continuity of care, including non-residential treatment services.
In the United States, the treatment of opioid dependence with opioid medications is governed by Federal Regulation 42 CFR, Part 8, which establishes a system based on accreditation and certification for opioid treatment programs. When there is more toxicity, treatment has a higher cost because side effects are also being dealt with or additional medications are being administered to try to prevent them. The Food and Drug Administration (FDA) recently approved a drug called lofexidine to help people who are trying to stop using opioids more easily than people who are trying to stop using opioids, which must be followed by treatment. The Institute of Medicine (IOM) report also notes that addressing substance use in the military will require increasing confidentiality and changing a cultural climate in which drug-related problems can be stigmatized and cause fear in people who suffer from them.
According to a survey conducted in May by the Gynecological Oncology Society, doctors in at least 40 states have a shortage of at least one chemotherapy drug. Teplinsky, an oncologist from New Jersey, has been encouraging her followers on social media to contact elected officials to advocate for the timely production of chemotherapy drugs and for long-term policies to ensure this doesn't happen again.